2025-12-04 - Analysis Report
Okay, here's a breakdown of the Recursion Pharmaceuticals (RXRX) analysis, covering the requested points and including simple numbers followed by basic analysis:

**0) Report Context:**

This report analyzes the current standing of Recursion Pharmaceuticals (RXRX) based on provided data, comparing it to the S&P 500 (VOO), examining recent stock performance, news, analyst opinions, and financial data.

**1) Return Rate Comparison:**

*   **RXRX Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI to discover and develop novel therapeutics.
*   **RXRX Cumulative Return:** -28.03%
*   **VOO (S&P 500) Cumulative Return:** 42.56%
*   **Divergence:** Current divergence is -69.5. Relative divergence: 2.7.

**Analysis:** RXRX has significantly underperformed the S&P 500 over the period examined. The cumulative return difference is substantial.  The very low relative divergence indicates that the current divergence between the two is near the minimum historically observed.

**Alpha, Beta Analysis:**

|            | CAGR  | MDD   | Alpha  | Beta  | Cap(B) |
|------------|-------|-------|--------|-------|--------|
| 2021-2023  | 22.0% | 81.0% | 26.0%  | -0.2  | 5.2    |
| 2022-2024  | 11.0% | 81.0% | -10.0% | 0.1   | 3.5    |
| 2023-2025  | 14.0% | 80.0% | -51.0% | 0.1   | 2.3    |

*   **CAGR:** Fluctuates with a downward trend from 22% to 14%.
*   **MDD:** Consistently high, indicating significant risk of substantial losses.
*   **Alpha:** Decreasing sharply over time, suggesting decreasing outperformance potential (or increasing underperformance).
*   **Beta:** Remains close to zero, indicating very low correlation with the S&P 500.
*   **Cap(B):**  Shows a downward trend, reflecting a decrease in market capitalization.

**Analysis:**  The company's historical performance shows high volatility (high MDD), and its performance relative to the market (Alpha) has deteriorated significantly.  The low Beta suggests that RXRX's price movements are not strongly tied to the broader market.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 4.445
*   **Last Market Data:** price': 4.445, 'previousClose': 4.32, 'change': 2.89}
*   **5-day SMA:** 4.454
*   **20-day SMA:** 4.4275
*   **60-day SMA:** 5.0779

**Analysis:** The current price is slightly above both the 5-day and 20-day SMAs, suggesting a short-term uptrend. However, it is significantly below the 60-day SMA, indicating that the longer-term trend might still be downward.  The recent 'change' suggests a recent positive fluctuation.

**3) RSI, PPO, and Other Indicators:**

*   **MRI:** 0.9 (Medium Investment Recommended)
*   **RSI:** 43.26
*   **PPO:** 1.11
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 1.9 (+): Short-term increase
*   **Expected Return (%):** -180.9%

**Analysis:**

*   The MRI indicates a "Medium Investment" recommendation.
*   The RSI is below 50, suggesting the stock is not overbought, but not significantly oversold either.
*   Positive PPO indicates a short-term upward trend.
*   The Hybrid Signal suggests a full investment with a fixed monthly investment.
*   The negative Expected Return is extremely concerning, implying potential significant losses if held long-term.

**4) Recent News & Significant Events:**

*   **AI Adoption:** Articles discuss RXRX's potential benefit from AI.
*   **New CEO:** Focus on the new CEO's impact on AI ambitions and partnerships.
*   **Earnings Report:** Analysts are revising their estimates after the third-quarter earnings report.
*   **TUPELO Trial Readout:** Upcoming webinar on clinical trial data.
*   **Dividend:** Discussion about continued dividend increases.

**Analysis:** Recent news is mixed. There's positive buzz around AI, a new CEO, and the upcoming trial data release. The discussion around earnings and analyst revisions suggests the market is closely watching the company's financial performance. The dividend discussion is irrelevant as RXRX has never paid dividends.

**4-2) Analyst Opinions:**

*   **Mean Rating:** Not provided (Indicates neutral opinion)
*   **Number of Opinions:** 6
*   **Target Price (avg/high/low):** 6.33 / 10.00 / 3.00

**Analysis:** Analysts have a slightly positive outlook, with an average target price significantly above the current price. However, the low target price of $3.00 indicates some analysts have a very bearish view.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-05 | -0.36 | 0.01 B$    |
| 2025-08-05 | -0.41 | 0.02 B$    |
| 2025-05-05 | -0.5  | 0.01 B$    |
| 2024-11-06 | -0.34 | 0.03 B$    |
| 2025-11-05 | -0.34 | 0.03 B$    |

**Analysis:** The company consistently reports negative EPS (losses). Revenue is relatively low. While revenue increased temporarily in 2024-11-06 (and 2025-11-05), it otherwise remains low.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.00B  | -194.74%       |
| 2025-06-30   | $0.02B  | -5.54%        |
| 2025-03-31   | $0.01B  | -47.31%       |
| 2024-12-31   | $0.00B  | -183.62%       |
| 2024-09-30   | $0.03B  | 53.69%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE       |
|--------------|---------|-----------|
| 2025-09-30   | $1.05B  | -15.50%    |
| 2025-06-30   | $0.92B  | -18.70%    |
| 2025-03-31   | $0.93B  | -21.68%    |
| 2024-12-31   | $1.03B  | -17.29%    |
| 2024-09-30   | $0.52B  | -18.27%    |

**Analysis:** Revenue is volatile and often very low.  Profit margins are consistently negative, except for one quarter. This implies the company is struggling to generate sustainable profits. ROE is consistently negative, showing the company is not generating a return on shareholder equity.

**7) Comprehensive Analysis (Summary):**

Recursion Pharmaceuticals (RXRX) faces significant challenges. It has substantially underperformed the S&P 500.  Its high MDD reflects a high level of risk. Recent news points to both positive catalysts (AI, new CEO) and potential concerns (earnings). While analyst target prices suggest upside potential, the wide range of targets indicates uncertainty. The company consistently reports losses and negative profit margins and ROE, raising concerns about its long-term financial viability. The negative Expected Return suggests a high degree of risk. The company's strategy is high-risk and long-term, so only suitable for investors with tolerance for this.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.